The Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document which will be involved in a report on voretigene neparvovec.
The therapy is currently under review by the U.S. Food and Drug Administration.
ICER says it will accept public comments on the Draft Scoping Document until July 31.
“The Draft Scoping Document was developed with input from key stakeholders, including groups representing the visually-impaired community and clinical experts, who provided important insights into the context of treatment decisions,” ICER said in the press release. “For example, conversations with representatives of the visually-impaired community highlighted the importance of outcomes beyond improvements in vision, including how available therapies and services can contribute to increased independence and productivity.”
The deadline for comments is 5 p.m. EST July 31. Comments can be emailed to email@example.com.